SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin D. Global burden of urinary bladder cancer. Scand J Urol Nephrol 2008; 218 (Suppl.): 1220
  • 2
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer staistics, 2007. CA Cancer J Clin 2007; 57: 4366
  • 3
    Cancer Research UK. Bladder cancer statistics-UK. 2011. Available at: http://info.cancerresearchuk.org/cancerstats/types/bladder. Accessed December 2011.
  • 4
    Shelley M, Cleves A, Wilt T, Mason M. Gemcitabine chemotherapy for the treatment of metastatic bladder cancer. BJU Int 2011; 108: 16879
  • 5
    Raj GV, Dalbagni G. Beyond BCG: gemcitabine. In Lee CT, Wood DP eds, Current Clinical Urology: Bladder Cancer, New York: Human Press, 2010: 45469
  • 6
    Gontero P, Casetta G, Maso G et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46: 33943
  • 7
    Dalbagni G, Russo P, Ben-Porat L et al. Phase II trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder. J Urol 2006; 175: 83942
  • 8
    Serretta V, Galuffo A, Pavone C, Allegro R, Pavone-MacAluso M. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005; 65: 659
  • 9
    Bartoletti R, Cai T, Gacci M et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005; 66: 72631
  • 10
    Addeo R, Caraglia M, Bellini S et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010; 28: 5438
  • 11
    Bendary L, Khalil S, Shahin A, Nawar N. Intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: a short term comparative study. J Urol 2011; 185: e6645
  • 12
    Bohle A, Leyh H, Frei C et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled Phase III multicentre study. Eur Urol 2009; 56: 495503
  • 13
    Gardmark T, Carringer M, Beckman E, Malmstrom PU, Members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology 2005; 66: 52730
  • 14
    Lorenzo G, Perdona S, Damiano R et al. Gemcitabine versus Bacillus Calmette-Guerin after initial Bacillus Calmette-Guerin failure in non-muscle invasive bladder cancer. Cancer 2010; 116: 1893900
  • 15
    Porena M, Del Zingaro M, Lazzeri M et al. Bacillus calmette-guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 2010; 84: 237
  • 16
    De Berardinis E, Antonini G, Autran Gomez AM, di Silverio F. Intravesical administration of Gemcitabine for the chemoresection of superficial bladder cancer ‘a marker lesion study’. Eur Urol Suppl 2004; 3: 123
  • 17
    Calais da Silva FM, Calais da Silva FE. Phase 2 study 2000 mg of intravesical gemcitabine in marker lesions. Eur Urol Suppl 2005; 4: 222
  • 18
    Brausi M, Giussani L, Altieri V, Rigatti P, Gontero P, Bono A. Phase II marker lesion study of 6-week intravesical gemcitabine instillation in patients with low risk non muscle invasive bladder tumours. Eur Urol Suppl 2007; 6: 59
  • 19
    Buettner H, Stoffregen C, Heyer J, Nentwig A, Boehle A. Immediate postoperative instillation of gemcitabine after transurethral rsection of bladder tumours. J Clin Oncol 2004; 22: 145. Abstract 4685
  • 20
    Iannelli A, Grifalchi F, Scirocchi R, Ceratti AD, Lagana A. Intravesical gemcitabine after transurethral resection in patients with superficial bladder cancer. Ann Oncol 2004; 15: 119
  • 21
    De Cataldis G, Esposito I, Carnicelli P, Barzelloni ML. Intravescical Gemcitabine therapy for superfical transitional cell carcinoma pTa-T1 G degrees 1/3 after transurethral resection. Ann Oncol 2005; 16: 801
  • 22
    Bounedjar A, Ferhat R, Bouzid K. A phase II study of intravesical gemcitabine as adjuvant therapy in patients (pts) with superficial bladder carcinoma: final results. Eur Urol Suppl 2005; 3: 249
  • 23
    Maffezzini M, Campodonico F, Canepa G, Capponi G, Fontana V. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol 2007; 51: 95661
  • 24
    Gunelli R, Bercovich E, Nanni O et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer 2007; 97: 1499504
  • 25
    Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 2008; 26: 6169
  • 26
    Morabito F, Rossi R, Graziano ME et al. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance. Arch Ital Urol Androl 2006; 78: 14
  • 27
    Perdona S, Di Lorenzo G, Cantiello F et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs 2010; 21: 1016
  • 28
    Breyer B, Whitson J, Carroll P, Konety B. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010; 28: 5104
  • 29
    Maymi JL, Saltsgaver N, O'Donnell MA. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 2006; 175: 840
  • 30
    Gacci M, Bartoletti R, Cai T et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int 2006; 76: 10611
  • 31
    Laufer M, Ramalingam S, Schoenberg MP et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21: 697703
  • 32
    Palou J, Antonio C, Segarra J et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. Eur Urol Suppl 2004; 3: 123
  • 33
    Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45: 1826
  • 34
    Mattioli F, Curotto A, Manfredi V et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res 2005; 25: 24936
  • 35
    Bassi P, De Marco V, Tavolini IM et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guerin therapy. Urol Int 2005; 75: 30913
  • 36
    Codacci-Pisanelli G, De Berardinis E, Di Silverio F, Giovannetti E, Mentuccia L, Peters GJ. Plasma pharmacokinetics of gemcitabine after intravesical administration. Proc Am Assoc Cancer Res 2005; 46: 9401
  • 37
    Maffezzini M, Campodonico F, Puntoni M, Martelli A, Mattioli F. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. Urology 2008; 74: 107883
  • 38
    Gontero P, Cattel L, Paone TC et al. Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU Int 2010; 106: 16526
  • 39
    Shelley M, Mason M, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010; 36: 195205
  • 40
    Shelley M, Wilt T, Court J, Coles B, Kynaston H, Mason M. Intravesical Bacillus Calmette-Guerin is superior to mitomycin C in reducing recurrence in high-risk superficial bladder cancer: a meta-analysis of randomised trials. BJU Int 2004; 93: 48590
  • 41
    Shelley M, Kynaston H, Court J, Wilt T, Coles B, Mason M. A systematic review of intravesical Bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder caner. BJU Int 2001; 88: 20916
  • 42
    De Braud F, Danesi R, Curigliano G et al. Pharmacogenetics determinants of anticancer activity of intravesical gemcitabine in patients with superficial transitional cell carcinoma of the bladder. Proc Am Assoc Cancer Res 2006; 47: 27, Abstract 3116